As the chart below illustrates, Antares Pharma (ATRS) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations.
(Courtesy StockCharts.com)
After reaching an intraday high near $4 in early March, the stock has not been able to break through its 50-day or 200-day moving averages, evidencing lower expectations for Xyosted since Jatenzo was approved.
Xyosted - Best-In-Class
While the prospect of an oral TRT appears to be game-changing, the underlying attributes of oral